VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, aiming to generate more clinically informative preclinical data while reducing the number of animals required for drug development. The Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (NAMs) in an October 7, 2026, company announcement. NAMs are a collection of non-animal research techniques that includes cell-based assays, computational modeling and other human-relevant systems.
The strategy supports development of the company’s BiTAC® T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer. VERAXA is implementing FDA-aligned NAMs across its preclinical research programs, seeking to improve the relevance of experimental findings to human biology while reducing animal testing. The move matters for investors and the broader oncology drug development field because preclinical models that better reflect human biology could improve the translation of experimental results into clinical outcomes, potentially reducing costly late-stage failures.
New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. In one ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer, about 10 mice were required, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. Those findings are important because they suggest the company’s human-relevant models can evaluate both target specificity and anti-tumor activity with far fewer animals, addressing a long-standing efficiency and ethical concern in preclinical research.
For readers following the company, the latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA. Additional details on the announcement are available through the VERAXA Biotech (NASDAQ: VRXA) client partner page, and the original release can be viewed on www.newmediawire.com. As with any forward-looking statement, actual results may differ materially from expectations due to risks and uncertainties, including those described in the company’s SEC filings.
